Evolva and Cargill to collaborate on second family of ingredients
Evolva Holding SA (“Evolva”; SIX: EVE) and Cargill have signed an agreement to co-develop a sustainable, customisable, and cost-effective fermentation production process for a second family of high-value food and beverage ingredients.
This additional collaboration between the two companies is modelled on the first partnership signed in March 2013 to develop next-generation stevia ingredients (steviol glycosides). This second family of high-value ingredients is unrelated to stevia. In the initial phase of the new collaboration, Evolva expects to deploy 5 – 7 researchers. Evolva and Cargill will share costs.
Neil Goldsmith, CEO of Evolva, commented: “Obviously, signing a second product collaboration agreement with Cargill—just under two years after starting our stevia collaboration with them—speaks to the confidence that both companies have about the fermentation route of production for a wide variety of functional ingredients. We are pleased that our relationship with Cargill continues to deepen.”
– Ends –
Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video
+ 41 61 485 2005
|Jakob Dynnes Hansen
+ 41 61 485 2034
+ 41 61 485 2035
THIS PRESS RELEASE CONTAINS SPECIFIC FORWARD-LOOKING STATEMENTS, E.G. STATEMENTS INCLUDING TERMS LIKE BELIEVE, ASSUME, EXPECT OR SIMILAR EXPRESSIONS. SUCH FORWARD LOOKING STATEMENTS ARE SUBJECT TO KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY RESULT IN A SUBSTANTIAL DIVERGENCE BETWEEN THE ACTUAL RESULTS, FINANCIAL SITUATION, DEVELOPMENT OR PERFORMANCE OF THE COMPANY AND THOSE EXPLICITLY OR IMPLICITLY PRESUMED IN THESE STATEMENTS. AGAINST THE BACKGROUND OF THESE UNCERTAINTIES READERS SHOULD NOT PLACE UNDUE RELIANCE ON FORWARD-LOOKING STATEMENTS OR TO ADAPT THEM TO FUTURE EVENTS OR DEVELOPMENTS.
Stay informed Join our mailing list to receive Evolva’s press releases via e-mail.Join